These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 9846579

  • 1. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S, Prussin C, Sacks DL, Seder RA.
    Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
    [Abstract] [Full Text] [Related]

  • 2. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.
    J Exp Med; 1997 Oct 06; 186(7):1137-47. PubMed ID: 9314562
    [Abstract] [Full Text] [Related]

  • 4. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P, Saxena S, Madhubala R.
    Vaccine; 2006 Mar 20; 24(13):2409-16. PubMed ID: 16413950
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M.
    Infect Immun; 2005 Sep 20; 73(9):5842-52. PubMed ID: 16113303
    [Abstract] [Full Text] [Related]

  • 6. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 20; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 7. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S, Ghaemimanesh F, Zahedifard F.
    Vaccine; 2006 Apr 12; 24(16):3290-7. PubMed ID: 16481076
    [Abstract] [Full Text] [Related]

  • 8. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.
    Exp Parasitol; 2011 Mar 07; 127(3):627-36. PubMed ID: 21187087
    [Abstract] [Full Text] [Related]

  • 10. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 07; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 11. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F, Di Roberto RB, Gillard J, Cousineau B.
    Vaccine; 2012 Aug 24; 30(39):5726-32. PubMed ID: 22814408
    [Abstract] [Full Text] [Related]

  • 12. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.
    Lange UG, Mastroeni P, Blackwell JM, Stober CB.
    Infect Immun; 2004 Aug 24; 72(8):4924-8. PubMed ID: 15271962
    [Abstract] [Full Text] [Related]

  • 13. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B.
    Infect Immun; 2004 Aug 24; 72(8):4521-7. PubMed ID: 15271911
    [Abstract] [Full Text] [Related]

  • 14. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
    Al-Wabel MA, Tonui WK, Cui L, Martin SK, Titus RG.
    Am J Trop Med Hyg; 2007 Dec 24; 77(6):1060-5. PubMed ID: 18165522
    [Abstract] [Full Text] [Related]

  • 15. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY.
    J Immunol; 1999 Aug 01; 163(3):1467-72. PubMed ID: 10415048
    [Abstract] [Full Text] [Related]

  • 16. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K, Akao S, Sato M, Nitta Y, Miyazaki J, Tadakuma T.
    Parasitol Int; 2001 Jul 01; 50(2):81-91. PubMed ID: 11438430
    [Abstract] [Full Text] [Related]

  • 17. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX, Barçante TA, Vilela L, Tafuri WL, Afonso LC, Vieira LQ.
    Immunol Lett; 2006 May 15; 105(1):38-47. PubMed ID: 16466810
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice.
    Gomes DC, Pinto EF, de Melo LD, Lima WP, Larraga V, Lopes UG, Rossi-Bergmann B.
    Vaccine; 2007 Mar 08; 25(12):2168-72. PubMed ID: 17240003
    [Abstract] [Full Text] [Related]

  • 20. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.
    Gabaglia CR, Sercarz EE, Diaz-De-Durana Y, Hitt M, Graham FL, Gauldie J, Braciak TA.
    Vaccine; 2004 Nov 25; 23(2):247-57. PubMed ID: 15531044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.